Drug Channels

OCTOBER 25, 2021

By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-name Drugs. The video is excerpted from my recent Drug Channels Update: Buy-and-Bill Trends video webinar.

Pharmacy 97

Pharmacy Drugs Pharmaceuticals Hospitals 97

Drug Channels

JUNE 1, 2020

Like many of you, I was disappointed that Asembia had to cancel its 2020 Specialty Pharmacy Summit. You can view them for FREE if your registration to the 2020 Specialty Pharmacy Summit was transferred to the 2021 Summit. Click here to register for access to Asembia’s Specialty Pharmacy Summit Virtual Experience.

Specialty Pharmacies 40

Specialty Pharmacies Pharmacy Pharmaceuticals Marketing 40

Drug Discovery World

FEBRUARY 10, 2023

DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. Scandinavia represents one of the most exciting but perhaps underrepresented markets for the discovery and development of pharmaceuticals.

Science 130

Science Drugs Pharmaceutical Companies Pharmaceuticals 130

Drug Channels

OCTOBER 1, 2024

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Last week, the Federal Trade Commission (FTC) released the redacted version of administrative complaint against the three largest pharmacy benefit managers (PBMs).

Biosimilars 52

Biosimilars Pharmacy Production FDA 52

Drug Channels

DECEMBER 1, 2020

During 2020, the COVID-19 pandemic disrupted every aspect of the pharmaceutical channel—and our lives. Pharmacy and healthcare provider markets experienced unprecedented volatility. If all goes well, 2021 will begin our return to normalcy, as vaccines roll out across the country. distribution channels for prescription drugs.

Pharmacy 52

Pharmacy Vaccine Drugs Pharmaceuticals 52

Drug Channels

JULY 20, 2021

The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others. As you will see below, mail and specialty pharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Marketing Pharmaceuticals 52

Drug Channels

DECEMBER 16, 2021

This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Outlook 2022. Click here to see the original post and comments from September 2021. Cardinal Health recently released the annual report for its 2021 fiscal year, which ended on June 30. drug purchaser.

Pharmaceuticals 98

Pharmaceuticals Drugs Pharmacy 98

Drug Channels

SEPTEMBER 3, 2020

This week, I’m rerunning some popular posts while I work on the forthcoming 2020-21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Last week, the Centers for Medicare and Medicaid Services (CMS) released its final Notice of Benefit and Payment Parameters for the 2021 benefit year.

Pharmacy 52

Pharmacy Pharmaceuticals Drugs 52

Drug Channels

SEPTEMBER 9, 2021

Cardinal Health recently released the annual report for its 2021 fiscal year, which ended on June 30. In Cardinal’s 2021 fiscal year, CVS purchased more than $42 billion in pharmaceuticals from the wholesaler—about double the figure from 10 years ago. drug purchaser. d/b/a Drug Channels Institute. to 1:30 p.m.

Pharmaceuticals 98

Pharmaceuticals Marketing Drugs Pharmacy 98

Drug Channels

MAY 19, 2020

Last week, the Centers for Medicare and Medicaid Services (CMS) released its final Notice of Benefit and Payment Parameters for the 2021 benefit year. This final rule permits insurers to exclude the value of a pharmaceutical manufacturer’s copay support program from a patient’s annual deductible and out-of-pocket maximum obligations.

Pharmacy 52

Pharmacy Pharmaceuticals Drugs 52

Drug Channels

MARCH 29, 2021

June 8-11, 2021 | Virtual Event www/informaconnect.com/medicaid-congress. Register today using the exclusive Drug Channels discount code 21MDGP10 to receive 10% off! Register today using the exclusive Drug Channels discount code 21MDGP10 to receive 10% off! Drug Channels, or any of its employees. Fresh Perspectives.

Government 52

Government Pharmacy Pharmaceuticals Production 52

Drug Channels

MARCH 29, 2021

June 8-11, 2021 | Virtual Event www/informaconnect.com/medicaid-congress. Register today using the exclusive Drug Channels discount code 21MDGP10 to receive 10% off! Register today using the exclusive Drug Channels discount code 21MDGP10 to receive 10% off! Drug Channels, or any of its employees. Fresh Perspectives.

Government 52

Government Pharmacy Pharmaceuticals Production 52

Drug Channels

OCTOBER 19, 2020

Get ready to hit the ground running in 2021 by closing out the year at Trade and Channel 2020 ! Drug Channels readers will save $300 off the standard rate when they use code GJE973 and register prior to October 30th.*. 16th Annual Life Sciences Trade and Channel Strategies. You can download the complete agenda here.

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Licensing 52

The Pharma Data

JUNE 29, 2021

Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective September 1, 2021. Dr. Kowalski is a senior drug development and regulatory executive with over 25 years of industry experience.

Pharmacy 52

Pharmacy Doctors Drug Development Science 52

Drug Channels

APRIL 11, 2021

June 15-17, 2021 | VIRTUAL EVENT (All-Digital Format). Drug Channels readers save 10% off the current registration rate with promo code 21PSSDC10.* Drug Channels, or any of its employees. Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. www.informaconnect.com/patient-support-services/.

Specialty Pharmacies 40

Specialty Pharmacies Compliance Pharmacy Pharmaceuticals 40

Drug Channels

JANUARY 4, 2021

March 3-5, 2021 | Virtual Event www.informaconnect.com/hub-spp. Drug Channels readers will save $100 off the current registration rate when they use code HUBSDC10*. Drug Channels readers will save $100 off the current registration rate when they use code HUBSDC10*. Drug Channels, or any of its employees. REGISTER TODAY !

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Production 52

Drug Channels

APRIL 19, 2021

June 22-24, 2021 | Virtual Event www.informaconnect.com/specialty-compliance/. Drug Channels, or any of its employees. To find out how you can reach the Drug Channels audience, please contact Paula Fein (paula@DrugChannels.net). Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Compliance 40

Compliance Production Specialty Pharmacies Pharmacy 40

Drug Channels

MAY 3, 2021

June 23-25, 2021 | Virtual Event informaconnect.com/contracts-chargebacks. Drug Channels readers are eligible for an exclusive savings of 10% off * the standard rate by using promo code 21CCCDC10 , so download the complete conference agenda and reserve your seat today! Drug Channels, or any of its employees.

Pharmacy 40

Pharmacy Government Pharmaceuticals Science 40

The Pharma Data

MAY 7, 2021

Posted 07 May 2021 | By Michael Mezher . Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug ( Endpoints ). Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug ( Endpoints ). Generic Drug Cos. In Focus: US. What happens now?

Vaccine 52

Vaccine Compounding Pharmacies Regulations Drugs 52

FDA Law Blog: Biosimilars

MAY 30, 2024

Kirschenbaum — Last week, the United States Court of Appeals for the District of Columbia ruled that Section 340B of the Public Health Service Act does not prohibit pharmaceutical manufacturers from imposing conditions on the distribution of discounted drugs to covered entities in the program. Novartis Pharmaceuticals v.

Pharmacy 59

Pharmacy Pharmaceuticals Government Hospitals 59

The Pharma Data

JANUARY 24, 2021

– January 25, 2021) – PharmaDrug Inc. Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceutical development expertise. Food and Drug Administration (“FDA”) approval.

FDA 52

FDA Drugs Clinical Development Pharmaceutical Companies 52

Drug Channels

JUNE 2, 2021

McKesson recently released the annual report for its 2021 fiscal year, which ended on March 31. As you will see, CVS purchased $50 billion in pharmaceuticals from McKesson—more than triple the figure from 10 years ago. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. to 1:30 p.m.

Pharmaceuticals 52

Pharmaceuticals Drugs Pharmacy 52

FDA Law Blog: Biosimilars

DECEMBER 4, 2023

Houck — Separate decisions by federal district courts in Texas and Puerto Rico in the past two months provide cautionary tales for every pharmacy and wholesale distributor dispensing or distributing controlled substances. This post examines the Zarzamora pharmacy and prescribing red flags decision. d/b/a CVS/Pharmacy, Nos.

Pharmacy 139

Pharmacy Government Treatment Compliance 139

Agency IQ

JANUARY 4, 2024

Pharmacopeia (USP) defines impurities as “any component of the drug substance that is not the chemical entity that is defined as the drug substance” or, “any component of a drug product that is not the drug substance or an excipient in the drug product.” Read AgencyIQ’s analysis of the ICH guideline here ].

FDA 40

FDA Production Laboratories FDA Approval 40

The Pharma Data

JANUARY 13, 2021

. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

DECEMBER 23, 2020

With news of a new Covid-19 variant spreading more rapidly than the original version in the UK, Pharma IQ has selected four updates that came out of the pharma industry in 2020, so you can begin the New Year with innovative solutions and research options to transform your pharma strategies for 2021. Source link.

Clinical Trials 52

Clinical Trials Vaccine FDA Trials 52

The Pharma Data

JANUARY 12, 2021

13, 2021 13:00 UTC. Akin to the NASA Deep Space Network, SYNERGY-AI OCTCC is a real time data and communication network between patients, sites, and pharmaceutical companies, with the Massive Bio AI-enabled engine orchestrating these stakeholders for successful operations. NEW YORK–( BUSINESS WIRE )– Massive Bio, Inc. ,

Clinical Trials 52

Clinical Trials Trials Clinical Research Pharmaceutical Companies 52

The Pharma Data

OCTOBER 30, 2020

Regeneron Pharmaceuticals, Inc. Food and Drug Administration , which is currently evaluating REGN-COV2 for a potential Emergency Use Authorization in mild-to-moderate outpatients at high risk for poor outcomes. Regeneron has partnered with Roche to increase the global supply of REGN-COV2 beginning in 2021. TARRYTOWN, N.Y. ,

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2020

Regeneron has partnered with Roche to increase the global supply of REGN-COV2 beginning in 2021. Department of Health and Human Services under OT number: HHSO100201700020C. If REGN-COV2 proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will manufacture and distribute it in the U.S.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Drug Discovery World

JULY 27, 2023

Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory Agency (MHRA). This agreement is called the Windsor Framework.

Government 130

Government Drugs Science International 130

The Pharma Data

JANUARY 3, 2021

4, 2021 /PRNewswire/ — CIMC Enric Holdings Limited (“ CIMC Enric ” or “ the Company “, SEHK stock code: 3899.HK), SHENZHEN, China , Jan. HK), announced that its subsidiary Zhangjiagang CIMC Sanctum Cryogenic Equipment Co.,

Vaccine 40

Vaccine Marketing Engineering Production 40

The Pharma Data

DECEMBER 17, 2020

17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. Regeneron continues to increase in-house production of casirivimab and imdevimab, and the company has partnered with Roche to increase the global supply beginning in 2021. None of the SAEs were considered to be related to study drug. TARRYTOWN, N.Y. ,

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

DECEMBER 5, 2020

Regeneron Pharmaceuticals, Inc. We are also expanding our odronextamab program with multiple pivotal trials in 2021.” About Regeneron Pharmaceuticals, Inc. 6 months of follow-up, 83% have ongoing responses for up to 13 months at the time of analysis.

Production 40

Production Trials Treatment Pharmaceuticals 40

The Pharma Data

JANUARY 12, 2021

12, 2021 /PRNewswire/ — . Regeneron Pharmaceuticals, Inc. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 None of the SAEs were considered to be related to study drug. TARRYTOWN, N.Y. , million doses.

Government 52

Government Hospitals Virus Production 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

Conditions for Coverage after January 1, 2025: Any manufacturer that wishes to have its applicable drugs covered under Medicare Part D after January 1, 2025 (“participating manufacturers”) must execute a Discount Program agreement with CMS by March 1, 2024. Non-applicable drugs (e.g.,

Compliance 105

Compliance Pharmacy Drugs Licensing 105

The Pharma Data

DECEMBER 29, 2020

Regeneron Pharmaceuticals, Inc. Food and Drug Administration (FDA) in high-risk patients who have confirmed COVID-19 but are not currently hospitalized. The company expects to complete the manufacture of these doses on schedule in January 2021 and is in discussions with the U.S. high dose, 0.9% low dose, 1.4% In the U.S.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

NOVEMBER 5, 2020

Regeneron Pharmaceuticals, Inc. In 2021, we look forward to important potential launches including for our PD-1 inhibitor Libtayo in non-small cell lung cancer and advanced basal cell carcinoma. Regulatory submissions in the United States and European Union (EU) are planned by the first quarter of 2021. Oncology Program.

Production 52

Production FDA FDA Approval Trials 52